TIZIANA LIFE SCIENCES LTD (TLSA) Stock News

USA - Nasdaq - NASDAQ:TLSA - BMG889121031 - Common Stock

1.77 USD

+0.08 (+4.73%)

Last: 12/4/2025, 4:30:01 PM

1.72 USD

-0.05 (-2.82%)

After Hours: 12/4/2025, 4:30:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TLSA Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

2 days ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

9 days ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

9 days ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

2 months ago - By: Stocktwits

News Image

Tiziana Life Sciences Stock Rises On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’

21 days ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

21 days ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

24 days ago - By: Benzinga - Mentions: TSLA

Elon Musk Says Tesla, xAI Are 'Trending Towards Convergence' In Some Ways

a month ago - By: Aquestive Therapeutics, Inc. - Mentions: AQST

Aquestive Therapeutics Announces Leadership Expansion to Support Growth

a month ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

3 months ago - By: Tiziana Life Sciences Ltd.

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

3 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

3 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

3 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Purchase of Shares by Chairman

3 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Purchase of Shares by Chairman

4 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

4 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

4 months ago - By: Tiziana Life Sciences Ltd.

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

4 months ago - By: Tiziana Life Sciences Ltd.

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

4 months ago - By: Benzinga - Mentions: UBER LCID TSLA

Lucid Is Now Shipping Adapters That Let Customers Access Elon Musk-Led Tesla's Supercharger Network

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the Bio International Convention

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the Bio International Convention

7 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

7 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

7 months ago - By: Tiziana Life Sciences Ltd.

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

7 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Purchase of Shares by Chairman

7 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab